Reactive oxygen species-dependent hypertension in dopamine D2 receptor-deficient mice

Hypertension

Volumn 49, Issue 3 PART 2 SUPPL., 2007, Pages 672-678

  Armando, Ines ^a   Wang, Xiaoyan ^a   Villar, Van Anthony M ^a   Jones, John E ^a   Asico, Laureano D ^a   Escano, Crisanto ^a   Jose, Pedro A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Genetics animal models; Hypertension, kidney; Mineralocorticoids

Indexed keywords

8 ISOPROSTANE; ALDOSTERONE; ANTIOXIDANT; APOCYNIN; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HEME OXYGENASE 1; HEME OXYGENASE 2; HEMIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SPIRONOLACTONE;

ADRENAL GLAND; ALDOSTERONE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; BLOOD PRESSURE; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME SUBUNIT; ESSENTIAL HYPERTENSION; HIGH SODIUM INTAKE; KIDNEY CORTEX; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; URINARY EXCRETION;

ALDOSTERONE; ANIMALS; ANTIOXIDANTS; BLOOD PRESSURE; HYPERTENSION; MICE; OXIDANTS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTORS, DOPAMINE D2;

EID: 33847013366     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000254486.00883.3d     Document Type: Conference Paper

References (42)

1. Jose PA, Eisner GM, Felder RA. Role of dopamine receptors in the kidney in the regulation of blood pressure. Curr Opin Nephrol Hypertens. 2002;11:87-92.
2. Hussain T, Lokhandwala MF. Renal dopamine receptors and hypertension. Exp Biol Med. 2003;228:134-142.
3. Zen C, Sanada H, Watanabe H, Eisner GM, Felder RA, Jose PA. Functional genomics of the dopaminergic system in hypertension. Physiol Genomics. 2004;19:233-246.
4. Jose PA, Eisner GM, Felder RA. Regulation of blood pressure by dopamine receptors. Nephron Physiol. 2003;95:19-27.
5. Sharma P, Fatibene J, Ferraro F, Jia H, Monteith S, Brown C, Clayton D, O'Shaughnessy K, Brown MJ. A genome-wide search for susceptibility loci to human essential hypertension. Hypertension. 2000;35:1291-1296.
6. Xu X, Rogus JJ, Terwedow HA, Yang J, Wang Z, Chen C, Niu T, Wang B, Xu H, Weiss S, Schork NJ, Fang Z. An extreme-sib-pair genome scan for genes regulating blood pressure. Am J Hum Genet. 1999;64:1694-1701.
7. Rosmond R, Rankinen T, Chagnon M, Perusse L, Chagnon YC, Bouchard C, Bjorntorp P. Polymorphism in exon 6 of the dopamine D(2) receptor gene (DRD2) is associated with elevated blood pressure and personality disorders in men. J Hum Hypertens. 2001;15:553-558.
8. Thomas GN, Tomlinson B, Critchley JA. Modulation of blood pressure and obesity with the dopamine D2 receptor gene Taq1 polymorphism. Hypertension. 2000;36:177-182.
9. Laaksoa A, Pohjalainena Tiina, Bergmanb Jorgen, Kajandera J, Haaparantac M, Solinb O, Syvalahtia E, Hietalad J. The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal L-amino acid decarboxylase in healthy subjects. Pharmacogenet Genomics. 2005;15:387-391.
10. Ritchie T, Noble EP. Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res. 2003;28:73-82.
11. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders A, Gelernter J, Gejman PV. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Human Molec Genet. 2003;12:205-216,
12. Bek MJ, Wang X, Asico LD, Jones JE, Zheng S, Li X, Eisner GMK, Grandy Dk, Carey RM, Soares-da-Silva P, Jose PA. Angiotensin-II type 1 receptor-mediated hypertension in D4 dopamine receptor-deficient mice. Hypertension. 2006;47:288-295.
13. Li XX, Bek M, Asico LD, Yang Z, Grandy DK, Goldstein DS, Rubinstein M, Eisner GM, Jose PA. Adrenergic and endothelin B receptor-dependent hypertension in dopamine receptor type-2 knockout mice. Hypertension. 2001;38:303-308.
14. Yang Z, Asico L, Yu P, Wang Z, Jones JE, Escano C, Wang X, Quinn MT, Sibley DR, Romero GG, Felder RA, Jose PA. D5 dopamine receptor regulation of reactive oxygen species production, NADPH oxidase and blood pressure. Am J Physiol. 2006;290:R96-R104.
15. Ueda A, Ozono R, Oshima T, Yano A, Kambe M, Teranishi Y, Katsuki M, Chayama K. Disruption of the type 2 dopamine receptor gene causes a sodium-dependent increase in blood pressure in mice. Am J Hypertens. 2003;16:853-858.
16. Wilcox CS. Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol. 2005;289:913-935.
17. Beswick RA, Dorrance AM, Leite R. Webb C. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension. 2001;38:1107-1111.
18. White BH, Sidhu A. Increased oxidative stress in renal proximal tubules of the spontaneously hypertensive rat: a mechanism for defective dopamine D1A receptor/G-protein coupling. J Hypertens. 1998;16:1659-1665.
19. Landmesser U, Cai H Dikalov V McCann L, Hwang J, Jo H Holland SM, Harrison DG. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension. 2002;40:511-515.
20. Grima G, Benz B, Parpura V, Cuenod M, Do KQ. Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophr Res. 2003;62:213-224.
21. Carvey PM, McGuire SO, Ling ZD. Neuroprotective effects of D3 dopamine receptor agonists. Parkinsonism Relat Disord. 2001;7:213-223.
22. Ishige K, Chen Q, Sagara Y, Schubert D. The activation of dopamine D4 receptors inhibits oxidative stress-induced nerve cell death. J Neurosci. 2001;21:6069-6076.
23. Noh JS, Gwag BJ. Attenuation of oxidative neuronal necrosis by a dopamine D1 agonist in mouse cortical cell cultures. Exp Neurol. 1997;146:604-608.
24. Asanuma M, Ogawa N, Nishibayashi S, Kawai M, Kondo Y, Iwata E. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain. Arch Int Pharmacodyn Ther. 1995;329:221-230.
25. Ogawa N, Tanaka K, Asanuma M, Kawai M, Masumizu T, Kohno M, Mori A. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res. 1994;657:207-213.
26. Zou L, Xu J, Jankovic J, He Y, Appel SH, Le W. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett. 2000;281:167-170.
27. Takashima H, Tsujihata M, Kishikawa M, Freed WJ. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors. Exp Neurol. 1999;159:98-104.
28. Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 1999;838:51-59.
29. Bokoch GM, Knaus UG. NADPH oxidases: not just for leukocytes anymore! Trends Biochem Sci. 2003;28:502-508.
30. Cai H, Griendling KK, Harrison DG The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci. 2003;24:471-478.
31. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ, Schiffrin EL. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res. 2002;90:1205-1213.
32. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension. 2003;42:1075-1081.
33. Zou AP, Cowley AW Jr. Reactive oxygen species and molecular regulation of renal oxygenation. Acta Physiol Scand. 2003;179:233-241.
34. Geiszt M, Koop JB, Varnai P, Leto TL. Identification of renox- an NAD(P)H oxidase in kidney. Proc Natl Acad Sci U S A. 2000;97:8010-8014.
35. Ray R, Shah AM. NADPH oxidase and endothelial cell function. Clinical Sci. 2005;109:217-226.
36. Zou A, Billington H, Su N, Cowley AW Jr. Expression and actions of Heme-Oxygenase in the renal medulla of rats. Hypertension. 2000;35:342-347.
37. da Silva, JL. Zand BA, Yang LM, Sabaawy HE, Lianos E, Abraham N. Heme oxygenase isoform-specific expression and distribution in the rat kidney. Kidney Int. 2001;59:1448-1457.
38. Carey RM, Thorner MO, Ortt E. Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man: dopaminergic control of aldosterone. J Clin Invest. 1979;63:727-735.
39. Virdis A, Fritsch Neves M, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504-510.
40. Park YM, Park MY, Suh Y-L, Park JB. NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. Biochem Biophys Res Comm. 2004;313:812-817.
41. Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, Shoki K, Yukimura T, Kiyimoto H, Kohno M, Abe Y, Nishiyama A. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol. 2005;16:2906-2912.
42. Nishiyama A, Yao L, Nagai Y, Miyata K, Koshizumi M, Kagami S, Kondo S, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension. 2004;43:841-848.